2025 Q4 -tulosraportti
Vain PDF
29 päivää sitten
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 341 | - | - | ||
| 2 148 | - | - | ||
| 488 | - | - | ||
| 1 058 | - | - | ||
| 2 454 | - | - |
Ylin
2,6VWAP
Alin
2,3VaihtoMäärä
0,1 25 982
VWAP
Ylin
2,6Alin
2,3VaihtoMäärä
0,1 25 982
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 25 982 | 25 982 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 25 982 | 25 982 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 9.10.2025 | ||
2025 H1 -tulosraportti 27.8.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenThis one will NEVER recover again !!!- ·26.2.Clearly this is heading for the abyss.
·27.2.What kind of comment is that? it's as if one is in Paradise Hotel, all sorts of immature comments everywhere.... If you think the company is heading towards an abyss, then you can just go somewhere else with your investments and comments. One doesn't need to comment on everything all the time, instead, go for a run, read a book or go to bed with your partner. 
·26.2.On Feb 4th, they announced that their formal annual report, which contains the complete financial figures for 2025, will be released on March 18th.
·23.2. · MuokattuIt is not sustainable for the case that there should be such long intervals between orders for a growth company with BQ’s visions. Difficult to see the light at the end of the tunnel despite the new Pharma director and the capital he brought into the company. I know history says it can be difficult to sell into new companies without a longer test phase, but with more than 2 months since the last order news, it honestly makes me more uncertain about the future. One can hope they have things in the pipeline that haven't been announced, but right now it's just the hope I'm holding onto 😅 Anyone more optimistic?·26.2.There is always a risk, of course - but with the growth they have announced, surely every single order shouldn't be written about, unless it's for a new sector etc.
·12.2.I have seen somewhat mixed opinions on the equipment the times I have encountered it in work contexts. I'm just not sure I fully understand the investment case. Isn't it "just" a total bacterial count based on an enzymatic assay? I understand there are some advantages compared to an ATP test, but it's probably still almost only relevant in contexts where total count makes sense. Unlike the food sector where there are tons of bacteria, and those you want to avoid are dangerous even in very small quantities.·18.2.For example, for Legionella, there is synergy between the total amount of biofilm and the risk of Legionella growth. So in many cases, the total amount will be perfectly OK. It therefore provides a good starting point for taking precautions.·18.2.That's right, but legionella specifically is one of those I've encountered who have sold a system. The complication arises when the customer then has to figure out the relationship between general bacterial load and legionella, and probably also between harmless legionella and dangerous legionella. That's not to say it can't easily be a great idea and that it can be done well. But market penetration will probably then depend on how quickly one can prove all the individual use cases, and whether one can get (or have oneself) an environment of implementation/applications experts. Again, not necessarily anything against the company's solution, I was just surprised that it is publicly listed, where patience is a bit lower.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
29 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenThis one will NEVER recover again !!!
- ·26.2.Clearly this is heading for the abyss.·27.2.What kind of comment is that? it's as if one is in Paradise Hotel, all sorts of immature comments everywhere.... If you think the company is heading towards an abyss, then you can just go somewhere else with your investments and comments. One doesn't need to comment on everything all the time, instead, go for a run, read a book or go to bed with your partner.
- ·26.2.On Feb 4th, they announced that their formal annual report, which contains the complete financial figures for 2025, will be released on March 18th.
- ·23.2. · MuokattuIt is not sustainable for the case that there should be such long intervals between orders for a growth company with BQ’s visions. Difficult to see the light at the end of the tunnel despite the new Pharma director and the capital he brought into the company. I know history says it can be difficult to sell into new companies without a longer test phase, but with more than 2 months since the last order news, it honestly makes me more uncertain about the future. One can hope they have things in the pipeline that haven't been announced, but right now it's just the hope I'm holding onto 😅 Anyone more optimistic?·26.2.There is always a risk, of course - but with the growth they have announced, surely every single order shouldn't be written about, unless it's for a new sector etc.
- ·12.2.I have seen somewhat mixed opinions on the equipment the times I have encountered it in work contexts. I'm just not sure I fully understand the investment case. Isn't it "just" a total bacterial count based on an enzymatic assay? I understand there are some advantages compared to an ATP test, but it's probably still almost only relevant in contexts where total count makes sense. Unlike the food sector where there are tons of bacteria, and those you want to avoid are dangerous even in very small quantities.·18.2.For example, for Legionella, there is synergy between the total amount of biofilm and the risk of Legionella growth. So in many cases, the total amount will be perfectly OK. It therefore provides a good starting point for taking precautions.·18.2.That's right, but legionella specifically is one of those I've encountered who have sold a system. The complication arises when the customer then has to figure out the relationship between general bacterial load and legionella, and probably also between harmless legionella and dangerous legionella. That's not to say it can't easily be a great idea and that it can be done well. But market penetration will probably then depend on how quickly one can prove all the individual use cases, and whether one can get (or have oneself) an environment of implementation/applications experts. Again, not necessarily anything against the company's solution, I was just surprised that it is publicly listed, where patience is a bit lower.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 341 | - | - | ||
| 2 148 | - | - | ||
| 488 | - | - | ||
| 1 058 | - | - | ||
| 2 454 | - | - |
Ylin
2,6VWAP
Alin
2,3VaihtoMäärä
0,1 25 982
VWAP
Ylin
2,6Alin
2,3VaihtoMäärä
0,1 25 982
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 25 982 | 25 982 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 25 982 | 25 982 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 9.10.2025 | ||
2025 H1 -tulosraportti 27.8.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 |
2025 Q4 -tulosraportti
Vain PDF
29 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 9.10.2025 | ||
2025 H1 -tulosraportti 27.8.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenThis one will NEVER recover again !!!
- ·26.2.Clearly this is heading for the abyss.·27.2.What kind of comment is that? it's as if one is in Paradise Hotel, all sorts of immature comments everywhere.... If you think the company is heading towards an abyss, then you can just go somewhere else with your investments and comments. One doesn't need to comment on everything all the time, instead, go for a run, read a book or go to bed with your partner.
- ·26.2.On Feb 4th, they announced that their formal annual report, which contains the complete financial figures for 2025, will be released on March 18th.
- ·23.2. · MuokattuIt is not sustainable for the case that there should be such long intervals between orders for a growth company with BQ’s visions. Difficult to see the light at the end of the tunnel despite the new Pharma director and the capital he brought into the company. I know history says it can be difficult to sell into new companies without a longer test phase, but with more than 2 months since the last order news, it honestly makes me more uncertain about the future. One can hope they have things in the pipeline that haven't been announced, but right now it's just the hope I'm holding onto 😅 Anyone more optimistic?·26.2.There is always a risk, of course - but with the growth they have announced, surely every single order shouldn't be written about, unless it's for a new sector etc.
- ·12.2.I have seen somewhat mixed opinions on the equipment the times I have encountered it in work contexts. I'm just not sure I fully understand the investment case. Isn't it "just" a total bacterial count based on an enzymatic assay? I understand there are some advantages compared to an ATP test, but it's probably still almost only relevant in contexts where total count makes sense. Unlike the food sector where there are tons of bacteria, and those you want to avoid are dangerous even in very small quantities.·18.2.For example, for Legionella, there is synergy between the total amount of biofilm and the risk of Legionella growth. So in many cases, the total amount will be perfectly OK. It therefore provides a good starting point for taking precautions.·18.2.That's right, but legionella specifically is one of those I've encountered who have sold a system. The complication arises when the customer then has to figure out the relationship between general bacterial load and legionella, and probably also between harmless legionella and dangerous legionella. That's not to say it can't easily be a great idea and that it can be done well. But market penetration will probably then depend on how quickly one can prove all the individual use cases, and whether one can get (or have oneself) an environment of implementation/applications experts. Again, not necessarily anything against the company's solution, I was just surprised that it is publicly listed, where patience is a bit lower.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 341 | - | - | ||
| 2 148 | - | - | ||
| 488 | - | - | ||
| 1 058 | - | - | ||
| 2 454 | - | - |
Ylin
2,6VWAP
Alin
2,3VaihtoMäärä
0,1 25 982
VWAP
Ylin
2,6Alin
2,3VaihtoMäärä
0,1 25 982
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 25 982 | 25 982 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 25 982 | 25 982 | 0 | 0 |